Vaccine Innovation Prioritisation Strategy

The Vaccine Innovation Prioritisation Strategy (VIPS) Alliance is a supranational collaborative initiative. It consists of the Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance, PATH, UNICEF and the World Health Organization.1)

Activities

Microarray patches

In May 2020, the VIPS Steering Committee selected and recommended three vaccine-related innovations to prioritize in order to increase uptake of vaccines. Microaray patches (MAPS) were identified as the highest priority (the other two were “heat-stable and controlled temperature chain qualified vaccines”, and barcodes on primary packaging).2) During the second half of 2020 and into 2021, the VIPS Working Group published a five-year plan to develop these MAPS.

MAPS are small devices that “consist of an array of hundreds to thousands of micro-projections on a patch or backing. These micro-projections can be coated with, or are composed of, vaccine in a dry formulation.” After being applied to the skin, the vaccine payload is delivered into the dermis and/or epidermis of the skin, which are rich in antigen-presenting cells. The two main types of MAPS being developed are solid-coated and dissolving.

A number of organizations are funding the development MAPS including the Bill & Melinda Gates Foundation, Biomedical Advanced Research and Development Authority (BARDA), the U.S. Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO). Developing companies include Micron Biomedical, the University of Connecticut, Vaxess, Vaxxas and Verndari.

VIPS estimates early pilot programs for MAPS will begin no earlier than 2026.

Personnel

VIPS Steering Committee3)
Name Affiliation Role
Alejandro Cravioto Universidad Nacional Autónoma de México Professor; SAGE Chair
David Robinson Bill & Melinda Gates Foundation Deputy Director of Vaccine Development and Surveillance, Chemistry Manufacturing and Controls
Christopher Morgan Jhpiego and Burnet Institute Senior Technical Advisor (Immunization) and Honorary Senior Principal Research Fellow
David Kaslow PATH Vice president, Essential Medicines
Jean-Pierre Amorij UNICEF Supply Division Vaccine Technology Specialist
Jerome Kim International Vaccine Institute Director General
Jon Abramson Wake Forest School of Medicine Professor of Pediatric Infectious Diseases
Kelly Moore Vanderbilt University School of Medicine Adjunct Associate Professor of Health Policy
Mark Jit London School of Hygiene and Tropical Medicine Professor, Vaccine Epidemiology
Mark Papania Centers for Disease Control and Prevention (CDC) Global Immunization Division Medical Epidemiologist
Michael Free Independent Independent Consultant; Senior Advisor Emeritus, PATH
Nora Dellepiane QRB Consultants Sàrl Independent consultant
Ramanan Laxminarayan Center for Disease Dynamics, Economics and Policy Director
Ruth Karron Johns Hopkins University Professor, International Health
Samir Sodha World Health Organization Routine Immunization Officer
Shelley Deeks Public Health Ontario Chief Health Protection Officer
1)
The Vaccine Innovation Prioritisation Strategy. (2021, June 30). Gavi, the Vaccine Alliance. https://archive.ph/eZMoO
2)
Vaccine Innovation Prioritisation Strategy (VIPS). (2021). Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan (p. 2). Gavi, the Vaccine Alliance. https://web.archive.org/web/20220806221838/https://www.gavi.org/sites/default/files/about/market-shaping/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf
3)
Vaccine Innovation Prioritisation Strategy. VIPS Steering Committee members. Gavi, the Vaccine Alliance. Retrieved August 6, 2022, from https://archive.ph/4ZbZG
Print/export